Category
7 articles
Machine learning models built on population-scale genomic datasets are producing diagnostic tools that work well for common conditions but fail patients with rare genetic disorders. The structural incentives that govern data contribution to open repositories help explain why this gap persists — and why the patients who most need AI-assisted diagnosis are the least likely to receive it.
A growing cohort of academic researchers and independent scientists is using publicly available datasets to reproduce proprietary cancer studies — and in doing so, surfacing errors, methodological inconsistencies, and overlooked findings that original publishers never corrected. The movement represents a fundamental challenge to the closed-access model that has long governed oncology research, and its results are beginning to influence how treatments are evaluated and approved.
Billions of federal dollars flow annually into biomedical research, yet the datasets those dollars produce are routinely locked behind institutional firewalls and subscription barriers. This investigation examines the legal, financial, and cultural forces that sustain this paradox — and profiles the researchers and institutions working to dismantle it.
Pharmaceutical companies submit vast quantities of safety and efficacy data to the FDA as part of the drug approval process — data that shapes prescribing decisions for millions of Americans but remains largely shielded from independent scientific review. This analysis argues that the current framework represents a structural failure of public health governance and examines what genuine transparency reform would demand.
Closed-source machine learning models embedded in peer-reviewed research are quietly undermining the scientific community's ability to verify its own findings. As retracted papers mount and frustration grows, researchers and open-science advocates are demanding a fundamental reckoning with computational opacity. The stakes extend well beyond academia—when algorithms cannot be examined, the public cannot trust the conclusions they produce.
Clinical trials for cancer therapies generate extraordinary volumes of patient data—yet most of it remains locked inside hospital networks, pharmaceutical archives, and private databases that rarely communicate with one another. Researchers attempting to identify drug interactions, treatment patterns, and survival predictors are working with incomplete pictures assembled from incompatible sources. A new generation of open-data advocates is fighting to change that, and early results suggest the s
A significant proportion of high-profile medical studies published in the United States cannot be reproduced by independent researchers — a systemic failure with profound consequences for patients, clinicians, and public trust in science. Open-access datasets and transparent research methodologies are emerging as the most credible structural solution to this crisis. This investigation examines why reproducibility collapsed, what it costs, and how institutions are beginning to rebuild.